[Economic aspects of polyvalent immunoglobulins].
Immunoglobulins differ from other drugs in several respects. In particular, they are derived from human plasma, which theoretically limits their availability, and their cost is sufficiently high to place economic pressure on the healthcare system. This implies the need for tight regulation. Immunoglobulin prescription is gradually increasing in France, and all new indications must be thoroughly assessed in prospective studies.